Adjuvant treatment for digestive tract tumors
Part of Cancer, Digestive system clinical trials.
This trial tests a treatment given after surgery to remove stomach or colorectal cancer. The goal is to see if it helps prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have had surgery to completely remove your stomach or colorectal cancer, and the cancer was at stage III.
- You have not had any chemotherapy, radiation, or targeted therapy before this surgery.
- You are generally healthy enough to undergo chemotherapy.
- You have not had other cancers in the last 3 years.
- You are willing to use effective birth control during the study and for 3 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (lenvatinib, tislelizumab, and CapeOX chemotherapy) as the first treatment for advanced stomach or gastroesophageal junction cancer that is PD-L1 positive and has a low TMEscore. The goal is to see if this combination helps control the cancer better than standard treatments.
This trial tests whether adding an anti-cancer immune treatment and another targeted drug to standard chemotherapy after surgery can lower the chance of cancer coming back. It is for people whose blood test (ctDNA) shows leftover cancer-related DNA after surgery.
This trial tests a new treatment plan after surgery for stomach cancer that shows certain markers, to reduce the chance of the cancer coming back. It includes drugs that help your immune system fight cancer.
This Phase 1/2 trial tests a combination treatment for advanced or metastatic stomach and food-pipe (gastroesophageal junction) cancer: a chemotherapy regimen (CapeOX) plus the immunotherapy drug sintilimab and the targeted drug bevacizumab. It aims to see how well this combination controls the cancer and how safely it can be given.
This trial studies which follow-up treatment is better for people with stomach or gastroesophageal junction cancer who had complete response to chemotherapy and immunotherapy before surgery, and whose tumor was completely removed. The goal is to reduce the chance of cancer coming back.
This trial compares a standard approach (chemotherapy and radiation before surgery) to a more intensive treatment (total neoadjuvant therapy plus radiation) for locally advanced rectal cancer. It aims to see if the stronger treatment helps remove the tumor and improves outcomes.
Hear when a new Adjuvant Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.